BR112017023948A2 - carboxamide low molecular weight derivatives of halogenated porphyrins, namely chlorins and bacteriochlorins and their applications - Google Patents

carboxamide low molecular weight derivatives of halogenated porphyrins, namely chlorins and bacteriochlorins and their applications

Info

Publication number
BR112017023948A2
BR112017023948A2 BR112017023948-5A BR112017023948A BR112017023948A2 BR 112017023948 A2 BR112017023948 A2 BR 112017023948A2 BR 112017023948 A BR112017023948 A BR 112017023948A BR 112017023948 A2 BR112017023948 A2 BR 112017023948A2
Authority
BR
Brazil
Prior art keywords
hydrogen
formula
carboxamide
alkyl
halogenated
Prior art date
Application number
BR112017023948-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Pereira Nascimento Costa Gonçalo
Paulo Ferreira Gonçalves Nuno
Jorge Pereira Monteiro Carlos
Carlos Reis De Abreu Artur
Tão Ferraz Cardoso Soares Hélder
Gabriel Borges Rocha Luis
Antonio Schaberle Fabio
Miguéns Pereira Maria
Guilherme Da Silva Arnaut Moreira Luis
Original Assignee
Luzitin, S.A.
Universidade De Coimbra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luzitin, S.A., Universidade De Coimbra filed Critical Luzitin, S.A.
Publication of BR112017023948A2 publication Critical patent/BR112017023948A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0093—Detecting, measuring or recording by applying one single type of energy and measuring its conversion into another type of energy
    • A61B5/0095—Detecting, measuring or recording by applying one single type of energy and measuring its conversion into another type of energy by applying light and detecting acoustic waves, i.e. photoacoustic measurements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Acoustics & Sound (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112017023948-5A 2015-05-07 2016-05-06 carboxamide low molecular weight derivatives of halogenated porphyrins, namely chlorins and bacteriochlorins and their applications BR112017023948A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PT108447 2015-05-07
PT10844715 2015-05-07
PCT/IB2016/052606 WO2016178191A1 (en) 2015-05-07 2016-05-06 Low molecular weight derivatives of carboxamide halogenated porphyrins, namely chlorins and bacteriochlorins, and their applications thereof

Publications (1)

Publication Number Publication Date
BR112017023948A2 true BR112017023948A2 (en) 2018-07-24

Family

ID=56084187

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017023948-5A BR112017023948A2 (en) 2015-05-07 2016-05-06 carboxamide low molecular weight derivatives of halogenated porphyrins, namely chlorins and bacteriochlorins and their applications

Country Status (11)

Country Link
US (1) US10450322B2 (https=)
EP (1) EP3292129B1 (https=)
JP (1) JP6730319B2 (https=)
CN (1) CN107624114B (https=)
AU (1) AU2016259188B2 (https=)
BR (1) BR112017023948A2 (https=)
CA (1) CA2985187C (https=)
HK (1) HK1245254A1 (https=)
RU (1) RU2718923C2 (https=)
WO (1) WO2016178191A1 (https=)
ZA (1) ZA201707533B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017214637A1 (en) 2016-06-10 2017-12-14 Nirvana Sciences Inc. Hydroporphyrin beads with narrow fluorescence emissions
CN110662748A (zh) * 2017-02-03 2020-01-07 尼尔瓦纳科学股份有限公司 用于光声成像的氢卟啉
US11904026B2 (en) 2017-02-03 2024-02-20 Nirvana Sciences Inc. Metallohydroporphyrins for photoacoustic imaging
CN109912607B (zh) * 2018-12-11 2021-01-22 南华大学 一类卟啉-白杨素复合物及其抗肿瘤活性
SG10201811547RA (en) * 2018-12-21 2020-07-29 Oreal Cosmetic use of a short chain fatty acid (scfa) for preventing and/or treating dry skin and/or aged skin
CN109651383B (zh) * 2019-01-25 2021-11-16 华东理工大学 用于光敏剂的化合物及其应用
WO2020236828A1 (en) * 2019-05-20 2020-11-26 Nirvana Sciences Inc. Narrow emission dyes, compositions comprising same, and methods for making and using same
US12570665B2 (en) 2019-06-10 2026-03-10 University Of Massachusetts Compositions comprising fullerenyl mesochlorin nano-photosensitizers with covalently bound antibiotics and their uses in combination therapy
CN116354970B (zh) * 2023-03-28 2024-06-18 大连理工大学 一种卟啉类一氧化碳前药的制备方法及气体-声动力联合治疗应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1480638A2 (en) * 2002-01-08 2004-12-01 Emory University Porphyrins with virucidal activity
FR2877943B1 (fr) * 2004-11-16 2008-09-05 Univ De Coimbra Nouveaux derives de porphyrine, notamment chlorines et/ou bacteriochlorine, et leurs applications en therapie photodynamique
GB0819594D0 (en) * 2008-10-24 2008-12-03 Univ Coimbrra Process
JP2013503895A (ja) * 2009-09-02 2013-02-04 ザ リージェンツ オブ ザ ユニバーシティー オブ コロラド，ア ボディー コーポレート 金属ポルフィリン類を使用するミトコンドリア病の処置法
WO2011099602A1 (ja) * 2010-02-12 2011-08-18 学校法人日本大学 ポルフィリン誘導体および放射線力学療法におけるその使用
BR112013001576A2 (pt) * 2010-07-22 2016-07-19 Ceramoptec Gmbh composto tetrapirrólico e composição farmacêutica derivado farmacêuticamente aceitável da mesma e respectivos usos e métodos de terapia fotodinâmica e de diagnóstico e tratamento da artrite e de doenças inflamatórias semelhantes.
CN102166182A (zh) * 2011-01-24 2011-08-31 上海交通大学 纳米探针及其在肿瘤诊断组合物和光动力疗法中的应用
US10456375B2 (en) * 2014-09-30 2019-10-29 Biolitec Unternehmensbeteiligungs Ii Ag Specifically meso-substituted porphyrins and chlorins for photodynamic therapy

Also Published As

Publication number Publication date
AU2016259188A1 (en) 2017-11-30
WO2016178191A1 (en) 2016-11-10
CN107624114A (zh) 2018-01-23
RU2017138871A3 (https=) 2019-06-11
JP6730319B2 (ja) 2020-07-29
JP2018515498A (ja) 2018-06-14
HK1245254A1 (zh) 2018-08-24
US10450322B2 (en) 2019-10-22
EP3292129A1 (en) 2018-03-14
CN107624114B (zh) 2021-03-23
RU2718923C2 (ru) 2020-04-15
AU2016259188B2 (en) 2019-10-31
ZA201707533B (en) 2019-04-24
RU2017138871A (ru) 2019-06-10
US20180282344A1 (en) 2018-10-04
CA2985187C (en) 2024-01-02
EP3292129B1 (en) 2019-03-27
CA2985187A1 (en) 2016-11-10

Similar Documents

Publication Publication Date Title
AU2016259188B2 (en) Low molecular weight derivatives of carboxamide halogenated porphyrins, namely chlorins and bacteriochlorins, and their applications thereof
ES2450136T3 (es) Proceso para la preparaci�n de clorinas y sus usos farmace�ticos
Kamkaew et al. BODIPY dyes in photodynamic therapy
Meng et al. Chlorin p6-based water-soluble amino acid derivatives as potent photosensitizers for photodynamic therapy
JP5205264B2 (ja) ペリレンキノン誘導体及びその使用
Warszynska et al. Better in the near infrared: Sulfonamide perfluorinated-phenyl photosensitizers for improved simultaneous targeted photodynamic therapy and real-time fluorescence imaging
PT2322173T (pt) Derivados catiónicos de bacterioclorofilas e utilizações dos mesmos
Zhu et al. Synthesis and biological evaluation of 173-dicarboxylethyl-pyropheophorbide-a amide derivatives for photodynamic therapy
Zhao et al. In vitro and in vivo evaluation of a chlorin-based photosensitizer KAE® for cancer treatment
Huang et al. Novel pyropheophorbide a dimers: Synthesis and photobiological evaluation as potent photosensitizers for photodynamic therapy
Wang et al. Synthesis and evolution of S-Porphin sodium as a potential antitumor agent for photodynamic therapy against breast cancer
Canyurt Efforts towards synthesis of hydrogen sulfide activated bodipy based pdt agent
Abdelaziz Synthesis And In Vitro Biochemical Evaluation of Porphyrin Derivatives For Photodynamic Anticancer Therapy
de Oliveira Braz Trans-A2B-Corroles are Superior Photosensitizers for Lung Cancer
Yan EVALUATION OF PORPHYRIN DERIVATIVE FOR PHOTODYNAMIC THERAPY
Kılıç Novel Near-Ir Photosensitizers for Photodynamic Therapy and Designing Heavy Atom Free Photosensitizers for the Photodynamic Therapy
BRPI0802649A2 (pt) derivados porfirìnicos, processo de obtenção e composição farmacêutica compreendendo os mesmos
HK1160848B (en) Process for preparing chlorins and their pharmaceutical uses

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2669 DE 03-03-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.